Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
Alzheimer’s disease (AD) is a severe neurodegenerative brain disorder. The determination of beta-amyloid (Aβ)-40, –42, total tau, and phospho-tau-181 (pTau181) in cerebrospinal fluid (CSF) using Lumipulse technology has been established as biomarkers for AD in recent years. As CSF collection is an i...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2022-09-01
|
| Rangatū: | Frontiers in Aging Neuroscience |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.1014305/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|